The primary aim of acquisition is to expand into high-entry barrier and super-specialty segments, particularly in women's health and fertility, where BSV has a strong presence
Read More
The non-exclusive patent license agreement allows Mankind Pharma to commercialise Vonoprazan, a potassium-competitive acid blocker (P-CAB), for the treatment of Gastroesophageal Reflux Disease (GERD) and other acid-related disorders
Read More
